|
Immunosuppression at 10 weeks
| | | |
|
CsA
|
99 (67%)
|
60 (77%)
|
ns
|
|
Tacrolimus
|
31 (21%)
|
10 (13%)
|
ns
|
|
mTOR inhibitor
|
14 (10%)
|
9 (12%)
|
ns
|
|
CsA dose (mg/day)
|
250.5 ± 73.5
|
255.4 ± 87.8
|
ns
|
|
CsA C0 concentration
|
151.4 ± 56.5
|
183.3 ± 85.6
|
0.01
|
|
Tacrolimus dose (mg/day)
|
5.65 ± 2.95
|
8.70 ± 4.64
|
ns
|
|
Tacrolimus concentration
|
7.3 ± 2.1
|
9.2 ± 2.3
|
ns
|
|
Prednisolone dose (mg/day)
|
12,4 ± 5.6
|
13.6 ± 5.6
|
ns
|
|
MMF (mg/day)
|
1678.1 ± 402.9
|
1750.0 ± 619.9
|
ns
|
|
Outcome
| | | |
|
Delayed graft function
|
53 (36%)
|
29 (35%)
|
ns
|
|
Acute rejection 90 days post transplant
|
29 (20%)
|
34 (41%)
|
0.001
|
|
Acute rejection 180 days post transplant
|
38 (26%)
|
35 (42%)
|
0.01
|
|
Steroid-resistant rejection (biopsy proven)
|
5 (3%)
|
18 (22%)
|
< 0.001
|
|
C4D positive biopsy
|
4 (5%)
|
4 (3%)
|
ns
|
|
Cause of graft loss
| | | |
|
Death with functioning graft
|
32 (22%)
|
24 (29%)
|
ns
|
|
Primary non-function
|
0
|
6 (7%)
|
0.002
|
|
Primary vascular thrombosis
|
3 (2%)
|
2 (2%)
|
ns
|
|
Rejection
|
5 (3%)
|
10 (12%)
|
0.02
|
|
Recurrent primary disease
|
0
|
1 (1%)
|
ns
|
|
Urological complications
|
1 (1%)
|
0
|
ns
|
|
De novo glomerulonephritis
|
1 (1%)
|
0
|
ns
|
|
Insufficient graft function
|
0
|
2 (2%)
|
ns
|
|
Not specified
|
2 (1%)
|
2 (2%)
|
ns
|
